Top View
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- Targeting Tumour Energy Metabolism Potentiates the Cytotoxicity of 5-Aminolevulinic Acid Photodynamic Therapy
- ― D03 - 1 ― 医学中央雑誌刊行会・医学用語シソーラス 第9版( 2019) カテゴリー別リスト
- (12) Patent Application Publication (10) Pub. No.: US 2016/0220537 A1 GARNER Et Al
- WO 2010/091198 Al
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- Inhibitors of the Menin-Mll Interaction Inhibitoren Der Menin-Mll-Interaktion Inhibiteurs De L’Interaction Ménine-Mll
- Review Article Reviving Lonidamine and 6-Diazo-5-Oxo-L-Norleucine to Be Used in Combination for Metabolic Cancer Therapy
- Nath, K., Guo, L., Nancolas, B., Nelson, D. S., Shestov, A. A., Lee, S- C., Roman, J., Zhou, R., Leeper, D
- Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice
- Supplementary Materials
- Revisiting Intrathecal Therapy in Infants and Children Sharon Conroy, Martin Garnett, Michael Vloeberghs, Richard Grundy, Ian Craven, David Walker
- PUBLICATION LIST Johan Moan 1. J.Moan
- Customs Tariff - Schedule Xxi - 1
- The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment
- Potentiation of the Effect of Lonidamine by Quercetin in MCF-7 Human Breast Cancer Cells Through Downregulation of MMP-2/9 Mrna Expression
- Antimycobacterial Activity of DNA Intercalator Inhibitors of Mycobacterium Tuberculosis Primase Dnag
- Preclinical Antitumour Activity of F 11782, a Novel Dual Catalytic Inhibitor of Topoisomerases
- Molecular Blueprints for Antitumor Drugs
- Downloads/Drugs/Guidancecomplianceregulatoryinformation/Guidances/ Ucm236669.Pdf [7] Zhao X, Chen Q, Li Y, Tang H, Liu W, Yang X
- Potential Therapies Targeting Metabolic Pathways in Cancer Stem Cells
- ICD-10-CM TABLE of DRUGS and CHEMICALS 2020
- Targeting Lonidamine to Mitochondria Mitigates Lung Tumorigenesis and Brain Metastasis
- Antitumour Treatment: Mitomycin C: a Clinical Update
- Mitochondrial Metabolism As a Target for Acute Myeloid Leukemia Treatment Svetlana B
- Lonidamine As a Modulator of Alkylating Agent Activity in Vitro and in Vivo1
- Compositions for Treating Breast Cancer
- Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk
- Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343
- Ep 3348266 A1
- ICD-10-CM Table of Drugs 2019
- 2U11/135459 A2
- Us 2019 / 0127401 A1
- Supporting Data : the Full List of Drugs with the PAD Scores. the "Known
- Lonidamine, Hyperthermia, and Chemotherapy Against the RIF-1 Tumor in Vivo1
- Antineoplastic Drugs
- The Anti-Tumour Agent Lonidamine Is a Potent Inhibitor of the Mitochondrial Pyruvate Carrier and Plasma Membrane Monocarboxylate Transporters